
    
      A prospective, open-ended, single-arm, phase II clinical study.Patients are with metastatic,
      recurrent, persistent cervical cancer (squamous cell carcinoma, adenocarcinoma, adenosquamous
      carcinoma) To observe the efficacy and safety of ZL-2306 (niraparib) combined with brivanib
      in patients with metastatic, recurrent and persistent cervical cancer, and to explore the
      biomarkers of effectiveness.
    
  